AU2020348489B2 - 4-substituted indole and indazole sulfonamido derivatives as PARG inhibitors - Google Patents
4-substituted indole and indazole sulfonamido derivatives as PARG inhibitorsInfo
- Publication number
- AU2020348489B2 AU2020348489B2 AU2020348489A AU2020348489A AU2020348489B2 AU 2020348489 B2 AU2020348489 B2 AU 2020348489B2 AU 2020348489 A AU2020348489 A AU 2020348489A AU 2020348489 A AU2020348489 A AU 2020348489A AU 2020348489 B2 AU2020348489 B2 AU 2020348489B2
- Authority
- AU
- Australia
- Prior art keywords
- thiadiazol
- difluoromethyl
- indazol
- amino
- sulfonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962903438P | 2019-09-20 | 2019-09-20 | |
| US62/903,438 | 2019-09-20 | ||
| PCT/US2020/051486 WO2021055744A1 (en) | 2019-09-20 | 2020-09-18 | 4-substituted indole and indazole sulfonamido derivatives as parg inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2020348489A1 AU2020348489A1 (en) | 2022-05-05 |
| AU2020348489B2 true AU2020348489B2 (en) | 2026-06-25 |
Family
ID=72744866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020348489A Active AU2020348489B2 (en) | 2019-09-20 | 2020-09-18 | 4-substituted indole and indazole sulfonamido derivatives as PARG inhibitors |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220389003A1 (enExample) |
| EP (1) | EP4031249B1 (enExample) |
| JP (2) | JP2022548690A (enExample) |
| KR (1) | KR20220066922A (enExample) |
| CN (1) | CN114555593A (enExample) |
| AU (1) | AU2020348489B2 (enExample) |
| BR (1) | BR112022004624A2 (enExample) |
| CA (1) | CA3147493A1 (enExample) |
| DK (1) | DK4031249T3 (enExample) |
| FI (1) | FI4031249T3 (enExample) |
| IL (1) | IL291436B1 (enExample) |
| LT (1) | LT4031249T (enExample) |
| MX (1) | MX2022003276A (enExample) |
| PT (1) | PT4031249T (enExample) |
| TW (1) | TWI873187B (enExample) |
| WO (1) | WO2021055744A1 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41179A (fr) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
| US20250002491A1 (en) | 2021-10-04 | 2025-01-02 | Forx Therapeutics Ag | N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer |
| CA3225500A1 (en) | 2021-10-04 | 2023-04-13 | Ulrich Luecking | Parg inhibitory compounds |
| IL311851A (en) * | 2021-10-04 | 2024-05-01 | Forx Therapeutics Ag | PARG inhibitory compounds |
| CA3251360A1 (en) | 2022-02-14 | 2023-08-17 | Arase Therapeutics Inc. | PARG INHIBITORS |
| EP4488275A4 (en) * | 2022-03-04 | 2025-07-23 | Shanghai Yingli Pharm Co Ltd | COMPOUND CONTAINING A FIVE-MEMBERED HETEROAROMATIC RING STRUCTURE, PHARMACEUTICAL COMPOSITION AND USE THEREOF |
| WO2023175184A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
| WO2023175185A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
| PL4496795T3 (pl) * | 2022-03-23 | 2026-07-20 | Ideaya Biosciences, Inc. | Związki indazolowe podstawione piperazyną jako inhibitory parg |
| IL316261A (en) | 2022-04-28 | 2024-12-01 | Danatlas Pharmaceuticals Co Ltd | Tricyclic and heterocyclic derivatives, preparations and uses thereof |
| TW202409036A (zh) | 2022-05-17 | 2024-03-01 | 美商858療法股份有限公司 | Parg抑制劑 |
| TWI878939B (zh) * | 2022-06-29 | 2025-04-01 | 大陸商杭州聖域生物醫藥科技有限公司 | 五元並六元含氮化物、其中間體、製備方法和應用 |
| AU2023310489A1 (en) * | 2022-07-19 | 2025-02-13 | Evopoint Biosciences Co., Ltd. | Sulfur-containing heteroaromatic ring compound, pharmaceutical composition thereof, and use thereof |
| EP4311829A1 (en) | 2022-07-28 | 2024-01-31 | Nodus Oncology Limited | Substituted bicyclic heteroaryl sulfonamide derivatives for the treatment of cancer |
| IL320031A (en) | 2022-10-03 | 2025-06-01 | Forx Therapeutics Ag | Parg inhibitory compound |
| CN120051465A (zh) * | 2022-10-13 | 2025-05-27 | 韩美药品株式会社 | 用于抑制yap-tead交互作用的新颖杂双环化合物及包含其的药学组成物 |
| EP4646208A1 (en) | 2023-01-06 | 2025-11-12 | Ideaya Biosciences, Inc. | Treatment of er+ breast cancer comprising homologous recombination deficiency using parg inhibitor |
| WO2024173234A1 (en) * | 2023-02-13 | 2024-08-22 | Arase Therapeutics Inc. | Inhibitors of parg |
| WO2024173530A1 (en) * | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Heteroaryl-substituted pyrazolo/imidazo pyridine compounds |
| WO2024173524A1 (en) * | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Heteroaryl-substituted benzimidazole compounds |
| WO2024173453A1 (en) * | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Heteroaryl-substituted imidazopyridine compounds |
| WO2024173514A1 (en) * | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Amide and ester-substituted imidazopyridine compounds |
| WO2024209035A1 (en) | 2023-04-05 | 2024-10-10 | Forx Therapeutics Ag | Parg inhibitory compounds |
| AU2024253809A1 (en) | 2023-04-05 | 2025-10-16 | Ideaya Biosciences, Inc. | Combination therapy comprising a parg inhibitor and a topoisomerase inhibitor for treating cancer |
| CN121002021A (zh) * | 2023-04-27 | 2025-11-21 | 北京丹擎医药科技有限公司 | 三环杂环衍生物及其组合物和应用 |
| WO2024254990A1 (zh) | 2023-06-16 | 2024-12-19 | 上海璎黎药业有限公司 | 一种杂芳环结构化合物、其药物组合物及应用 |
| WO2025046148A1 (en) | 2023-09-01 | 2025-03-06 | Forx Therapeutics Ag | Novel parg inhibitors |
| WO2025064750A1 (en) | 2023-09-20 | 2025-03-27 | Ideaya Biosciences, Inc. | Combination therapy with a parg inhibitor |
| TW202528308A (zh) * | 2023-09-20 | 2025-07-16 | 美商愛德亞生物科學公司 | Parg抑制劑 |
| WO2025072544A1 (en) * | 2023-09-27 | 2025-04-03 | Ideaya Biosciences, Inc. | Sulfonamino indazole compounds as inhibitors of parg |
| WO2025067464A1 (zh) * | 2023-09-28 | 2025-04-03 | 杭州圣域生物医药科技有限公司 | 杂芳基化合物、其中间体、制备方法和应用 |
| KR20260084620A (ko) | 2023-10-03 | 2026-06-05 | 포알엑스 테라퓨틱스 아게 | Parg 억제 화합물 |
| WO2025082231A1 (zh) * | 2023-10-20 | 2025-04-24 | 上海璎黎药业有限公司 | 一种杂芳环磺酰胺结构化合物、其药物组合物及应用 |
| WO2025087941A1 (en) | 2023-10-23 | 2025-05-01 | Universite De Geneve | Parg inhibitors in combination with parp inhibitors and uses thereof |
| CN122249439A (zh) | 2023-10-26 | 2026-06-19 | 上海齐鲁制药研究中心有限公司 | Parg抑制剂 |
| WO2025087274A1 (zh) | 2023-10-27 | 2025-05-01 | 浙江海正药业股份有限公司 | 氮杂双环类衍生物及其制备方法和用途 |
| WO2025093755A1 (en) | 2023-11-01 | 2025-05-08 | Forx Therapeutics Ag | Novel parc inhibitors |
| WO2025098445A1 (zh) * | 2023-11-07 | 2025-05-15 | 南京同诺康医药科技有限公司 | Parg抑制剂及其制备方法和用途 |
| WO2025108225A1 (zh) * | 2023-11-20 | 2025-05-30 | 上海复星医药（集团）股份有限公司 | 作为parg抑制剂的含氮三环衍生物 |
| WO2025111339A1 (en) * | 2023-11-21 | 2025-05-30 | 858 Therapeutics, Inc. | Treatment of cancer with a parg inhibitor |
| AR134429A1 (es) * | 2023-11-22 | 2026-01-14 | 858 Therapeutics Inc | Inhibidores de parg |
| WO2025133396A1 (en) | 2023-12-22 | 2025-06-26 | Forx Therapeutics Ag | Novel bicyclo heteroaryl parg inhibitors |
| WO2025133191A1 (en) * | 2023-12-22 | 2025-06-26 | Genecode | Novel sulfonamides or sulfones and their use as neuroprotective and/or neurorestorative agents |
| WO2025229549A1 (en) * | 2024-04-30 | 2025-11-06 | Satyarx Pharma Innovations Pvt Ltd | Novel heterocyclic compounds as inhibitors of parg |
| CN118459452B (zh) * | 2024-07-10 | 2024-10-25 | 苏州国匡医药科技有限公司 | 一种多聚adp核糖水解酶抑制剂及其应用 |
| WO2026022150A1 (en) | 2024-07-22 | 2026-01-29 | Forx Therapeutics Ag | Parg inhibitory compounds |
| TW202610628A (zh) * | 2024-07-29 | 2026-03-16 | 大陸商海思科醫藥集團股份有限公司 | 磺醯胺化合物及其在醫藥上的應用 |
| WO2026032385A1 (zh) * | 2024-08-07 | 2026-02-12 | 上海亚虹医药科技有限公司 | 多聚adp核糖水解酶抑制剂及其医药用途 |
| WO2026040953A1 (zh) * | 2024-08-19 | 2026-02-26 | 上海和誉生物医药科技有限公司 | 一种多环parg抑制剂和其应用 |
| WO2026042050A1 (en) * | 2024-08-23 | 2026-02-26 | Recursion Pharmaceuticals, Inc. | Novel compounds and uses thereof |
| WO2026060261A1 (en) * | 2024-09-13 | 2026-03-19 | Equator Therapeutics, Inc. | Compositions and methods for treating metabolic disorders |
| WO2026062066A1 (en) | 2024-09-17 | 2026-03-26 | Forx Therapeutics Ag | Compounds inducing parg degradation |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016097749A1 (en) * | 2014-12-19 | 2016-06-23 | Cancer Research Technology Limited | Parg inhibitory compounds |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| CA2242425C (en) | 1996-02-13 | 2006-07-18 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| EE05345B1 (et) | 1999-02-10 | 2010-10-15 | Astrazeneca Ab | Kinasoliini derivaadid angiogeneesi inhibiitoritena |
| BR0111230A (pt) | 2000-05-31 | 2003-06-10 | Astrazeneca Ab | Composto, e, uso e processo para a preparação do mesmo |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| KR20030014425A (ko) | 2000-07-07 | 2003-02-17 | 앤지오젠 파마슈티칼스 리미티드 | 혈관 손상제인 콜치놀 유도체 |
| EE200300015A (et) | 2000-07-07 | 2004-10-15 | Angiogene Pharmaceuticals Limited | Kolhinooli derivaadid kui angiogeneesi inhibiitorid |
| CA2834101A1 (en) * | 2011-01-07 | 2012-07-12 | Taiho Pharmaceutical Co., Ltd. | Novel indole or indazole derivative or salt thereof |
| MA41140A (fr) * | 2014-12-12 | 2017-10-17 | Cancer Research Tech Ltd | Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg |
| AU2018352695A1 (en) * | 2017-10-19 | 2020-05-28 | Effector Therapeutics, Inc. | Benzimidazole-indole inhibitors of Mnk1 and Mnk2 |
| PT3870575T (pt) * | 2018-10-25 | 2023-05-12 | Viiv Healthcare Uk No 5 Ltd | Inibidores da replicação do vírus da imunodeficiência humana |
| PL4496795T3 (pl) * | 2022-03-23 | 2026-07-20 | Ideaya Biosciences, Inc. | Związki indazolowe podstawione piperazyną jako inhibitory parg |
-
2020
- 2020-09-17 IL IL291436A patent/IL291436B1/en unknown
- 2020-09-18 TW TW109132483A patent/TWI873187B/zh active
- 2020-09-18 MX MX2022003276A patent/MX2022003276A/es unknown
- 2020-09-18 FI FIEP20786137.8T patent/FI4031249T3/fi active
- 2020-09-18 US US17/761,935 patent/US20220389003A1/en active Pending
- 2020-09-18 KR KR1020227012903A patent/KR20220066922A/ko active Pending
- 2020-09-18 EP EP20786137.8A patent/EP4031249B1/en active Active
- 2020-09-18 DK DK20786137.8T patent/DK4031249T3/da active
- 2020-09-18 CN CN202080065861.1A patent/CN114555593A/zh active Pending
- 2020-09-18 WO PCT/US2020/051486 patent/WO2021055744A1/en not_active Ceased
- 2020-09-18 BR BR112022004624A patent/BR112022004624A2/pt unknown
- 2020-09-18 PT PT207861378T patent/PT4031249T/pt unknown
- 2020-09-18 LT LTEPPCT/US2020/051486T patent/LT4031249T/lt unknown
- 2020-09-18 AU AU2020348489A patent/AU2020348489B2/en active Active
- 2020-09-18 JP JP2022517374A patent/JP2022548690A/ja not_active Ceased
- 2020-09-18 CA CA3147493A patent/CA3147493A1/en active Pending
-
2024
- 2024-11-01 JP JP2024193094A patent/JP7781244B2/ja active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016097749A1 (en) * | 2014-12-19 | 2016-06-23 | Cancer Research Technology Limited | Parg inhibitory compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114555593A (zh) | 2022-05-27 |
| JP7781244B2 (ja) | 2025-12-05 |
| JP2025016684A (ja) | 2025-02-04 |
| BR112022004624A2 (pt) | 2022-05-31 |
| MX2022003276A (es) | 2022-04-11 |
| LT4031249T (lt) | 2026-08-10 |
| WO2021055744A1 (en) | 2021-03-25 |
| PT4031249T (pt) | 2026-07-16 |
| DK4031249T3 (da) | 2026-07-27 |
| JP2022548690A (ja) | 2022-11-21 |
| TWI873187B (zh) | 2025-02-21 |
| CA3147493A1 (en) | 2021-03-25 |
| IL291436A (en) | 2022-05-01 |
| US20220389003A1 (en) | 2022-12-08 |
| KR20220066922A (ko) | 2022-05-24 |
| FI4031249T3 (fi) | 2026-07-23 |
| IL291436B1 (en) | 2026-07-01 |
| EP4031249A1 (en) | 2022-07-27 |
| AU2020348489A1 (en) | 2022-05-05 |
| EP4031249B1 (en) | 2026-06-17 |
| TW202120501A (zh) | 2021-06-01 |